Published in Cancer Res on October 11, 2013
Reporter nanoparticle that monitors its anticancer efficacy in real time. Proc Natl Acad Sci U S A (2016) 0.78
Interaction between IGFBP7 and insulin: a theoretical and experimental study. Sci Rep (2016) 0.75
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A (1999) 11.38
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
The PI3K pathway as drug target in human cancer. J Clin Oncol (2010) 6.83
The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer (2004) 5.47
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature (2005) 4.97
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2011) 4.77
Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 4.02
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res (1994) 3.54
Toward complex matter: supramolecular chemistry and self-organization. Proc Natl Acad Sci U S A (2002) 2.75
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J (2007) 2.66
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther (2009) 2.43
Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res (2010) 2.30
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res (2011) 2.19
A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res (2009) 1.72
Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci U S A (2012) 1.32
Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A (2012) 1.03
A small MRI contrast agent library of gadolinium(III)-encapsulated supramolecular nanoparticles for improved relaxivity and sensitivity. Biomaterials (2010) 1.02
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. J Clin Oncol (2011) 0.98
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis (2009) 0.90
Exploiting nanotechnology to target cancer. Br J Cancer (2007) 0.89
PIKing the right patient. Clin Cancer Res (2010) 0.86
Design principles for clinical efficacy of cancer nanomedicine: a look into the basics. ACS Nano (2013) 0.86
Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem J (2012) 0.83
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science (2010) 6.01
Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A (2002) 5.35
Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater (2009) 4.77
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell (2009) 4.02
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater (2011) 3.83
Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle (2007) 3.62
Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A (2007) 3.26
Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell (2004) 3.09
A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med (2002) 2.77
Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol (2003) 2.68
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell (2003) 2.56
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A (2009) 2.41
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci U S A (2002) 2.35
Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem (2007) 2.31
Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. Small (2009) 2.16
Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res (2008) 2.13
India's R&D: reaching for the top. Science (2005) 2.08
Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell (2003) 2.07
Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. Mol Cell Biol (2010) 2.05
Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A (2002) 2.01
Magnetic Iron Oxide Nanoworms for Tumor Targeting and Imaging. Adv Mater (2008) 2.01
In vivo tumor cell targeting with "click" nanoparticles. Bioconjug Chem (2008) 2.01
Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine (2008) 1.90
Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model. Kidney Int (2013) 1.83
Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc Natl Acad Sci U S A (2009) 1.82
Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A (2004) 1.82
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A (2012) 1.81
Evaluation of automated brain MR image segmentation and volumetry methods. Hum Brain Mapp (2009) 1.79
Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A (2009) 1.76
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila) (2009) 1.75
A mitochondrial protein, Bit1, mediates apoptosis regulated by integrins and Groucho/TLE corepressors. Cell (2004) 1.73
Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed Engl (2008) 1.71
Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci U S A (2006) 1.68
Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci U S A (2011) 1.68
Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell (2012) 1.56
R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat Med (2005) 1.51
Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis. Proc Natl Acad Sci U S A (2011) 1.45
Crystal structure of a human peptidyl-tRNA hydrolase reveals a new fold and suggests basis for a bifunctional activity. J Biol Chem (2003) 1.44
Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med (2012) 1.42
Proteolytic actuation of nanoparticle self-assembly. Angew Chem Int Ed Engl (2006) 1.39
Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci U S A (2013) 1.37
Nanoparticle-induced vascular blockade in human prostate cancer. Blood (2010) 1.30
Rapid self-healing hydrogels. Proc Natl Acad Sci U S A (2012) 1.29
Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A (2002) 1.26
Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery. Adv Mater (2010) 1.26
A high-throughput label-free nanoparticle analyser. Nat Nanotechnol (2011) 1.24
Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res (2010) 1.23
Cell spreading controls endoplasmic and nuclear calcium: a physical gene regulation pathway from the cell surface to the nucleus. Proc Natl Acad Sci U S A (2003) 1.22
Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Res (2006) 1.22
Anastellin, an FN3 fragment with fibronectin polymerization activity, resembles amyloid fibril precursors. J Mol Biol (2003) 1.21
Mapping of vascular ZIP codes by phage display. Methods Enzymol (2012) 1.21
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci U S A (2010) 1.20
Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis (2006) 1.19
Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials (2009) 1.19
Lymphatic zip codes in premalignant lesions and tumors. Cancer Res (2006) 1.18
Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One (2009) 1.17
Focused glycomic analysis of the N-linked glycan biosynthetic pathway in ovarian cancer. Proteomics (2008) 1.17
Compound library development guided by protein structure similarity clustering and natural product structure. Proc Natl Acad Sci U S A (2004) 1.17
p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. Anticancer Res (2009) 1.13
Synthetic surfaces for human embryonic stem cell culture. J Biotechnol (2010) 1.13
De novo design of a tumor-penetrating peptide. Cancer Res (2012) 1.12
Role of cyclophilin D in the resistance of brain mitochondria to the permeability transition. Neurobiol Aging (2006) 1.12
Molecular profiling of heart endothelial cells. Circulation (2005) 1.11
Protein kinase D is a positive regulator of Bit1 apoptotic function. J Biol Chem (2008) 1.11
Anoikis effector Bit1 negatively regulates Erk activity. Proc Natl Acad Sci U S A (2008) 1.11
Lymphangiogenesis and cancer: meeting report. Cancer Res (2004) 1.10
Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol Cancer Res (2007) 1.10
Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature. Proc Natl Acad Sci U S A (2005) 1.10
Molecular changes in the vasculature of injured tissues. Am J Pathol (2007) 1.08
Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature. Angiogenesis (2009) 1.08
A surface-charge study on cellular-uptake behavior of F3-peptide-conjugated iron oxide nanoparticles. Small (2009) 1.07
Tumor-penetrating peptides. Front Oncol (2013) 1.06
Effect of the lipid chain melting transition on the stability of DSPE-PEG(2000) micelles. Langmuir (2009) 1.06
Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci U S A (2009) 1.06
Antiangiogenic proteins require plasma fibronectin or vitronectin for in vivo activity. Proc Natl Acad Sci U S A (2003) 1.04
alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+/calmodulin-dependent protein kinase IV. J Cell Biochem (2005) 1.04
Dynamic imaging of arginine-rich heart-targeted vehicles in a mouse model. Biomaterials (2008) 1.03
Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A (2012) 1.03
Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer. J Mol Diagn (2012) 1.03